Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms

DOI: 10.1158/1055-9965.EPI-07-0481 Published November 2007

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
ESR1 (TA)_n distribution by case/control status. Global P = 0.08. Contrasts with ESR1 (TA)₁₄ indicated with a “*” P < 0.05.
Download figure
Open in new tab
Download powerpoint
Figure 2.
ESR2 (CA)_n distribution by case/control status. Global P = 0.69.

Table 1.

Study participants by level of covariates and case-control status

	Cases (n = 545)	Controls (n = 674)
Age at baseline,* mean (SD)	61.09 (7.35)	61.20 (7.64)
Weight (kg), mean (SD)	79.22 (9.40)	77.77 (9.50)
Height (cm), mean (SD)	178.76 (6.14)	177.95 (6.84)
Smoking,* n (%)
Current smokers	42 (7.71)	57 (8.46)
Former smokers	251 (46.06)	315 (46.74)
Tumor grade, n (%)
Gleason ≥7 or poorly differentiated	190 (34.86)
Gleason <7 or well differentiated	296 (54.31)
Unknown	59 (10.83)
Stage, n (%)
Died of prostate cancer	117 (21.47)
Diagnosed with Metastases	16 (2.94)
Whitmore-Jewett stage C or D at initial diagnosis	86 (15.78)
Whitmore-Jewett stage A or B at initial diagnosis	277 (50.83)
Unknown	49 (8.99)